On October 12, 2023, the Bellerophon’s board of directors approved a plan of liquidation and dissolution.

Further inquiries can be directed to Verdolino & Lowey, P.C. Bellerophon@vlpc.com

Bellerophon Therapeutics, Inc. filings with the Securities and Exchange Commission are available at https://www.sec.gov/edgar/browse/?CIK=1600132&owner=exclude